Due Diligence Best Practices from Pharma Leaders

Through due diligence, investors and pharma companies take a closer look at their potential partner, the asset, and the deal itself to validate claims and evaluate risks. With many millions of dollars riding on the success of licensing and acquisition activities, a deal gone wrong can mean significant debt and wasted resources.

This eBook gathers best practices from top pharma companies and offers actionable steps for improving due diligence at life science companies of all sizes.


Please complete the form below

All fields marked with a * are required.

Create a structured evaluation process

There are a lot of moving parts involved in due diligence, a well-defined process and structure play a critical role in maintaining efficiency and impact. An effective way to structure the due diligence process, as explained in this Inova webinar, is to use themes and subthemes for each functional area to guide their experts.

Each theme is rated against an internal standard. For example, if the partner says the asset is Phase II ready, the experts will evaluate whether it fits their company’s standard for a Phase II ready asset.

Evaluation of Data Package Content and Quality

Significant Strength

Significantly exceeds internal standard

Better internal criteria: a potential benchmark

Moderate Strength

Exceeds internal standard

Somewhat better than internal criteria


Meets internal standard

Consistent with internal criteria

Moderate Gap

Below internal standard

Somewhat below internal criteria

Significant Gap

Significantly below internal standard

Markedly below internal criteria

Kick off the due diligence together
Filter & prioritize information requests
Document the history of your diligence
Preview eBook

8 Best Practices from Top Pharma companies

  • Kick off the due diligence together.

  • Filter & prioritize information requests.
  • Document the history of your diligence.

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.